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Background: Management of abortion is an important issue in gynecology. Several millions of spontaneous abortions occur yearly and 
more than a million induced abortions are performed in the USA.
Objectives: The aim of this study was to compare the effect of misoprostol alone and misoprostol with letrozole in the induction of 
abortion in the first trimester of pregnancy in the Qazvin city of Iran.
Patients and Methods: Seventy female candidates for legal abortion within the first trimester of pregnancy were divided to two groups: 
misoprostol alone and misoprostol with letrozole. The complete abortion, time to open the internal os of the cervix, time to complete the 
abortion, and drug-induced side effects of misoprostol and letrozole were recorded and analyzed.
Results: The complete abortion rate was 69.7% in the misoprostol and letrozole group and 30.3% in the misoprostol group. Incomplete 
abortion was 32.4% in the misoprostol and letrozole group, and 67.6% in the misoprostol group (P = 0.004). Bleeding, cervix os opening 
time, and time to complete abortion from induction of drugs were similar in both groups (P > 0.05). There were no medical complications 
in both groups.
Conclusions: Misoprostol plus letrozole was more effective for inducing abortion in the first trimester of pregnancy compared to 
misoprostol alone.
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1. Background
According to the national center of vital statistics, centers 
for disease control and prevention and the world health 
organization definition, abortion is the termination of a 
pregnancy before the 20th week of pregnancy or termina-
tion of pregnancy before the fetus weighing 500 g (1, 2).
Abortion management is an important issue in gyne-
cology. Several millions of spontaneous abortions occur 
yearly and more than a million induced abortions are an-
nually performed in the USA. Induced abortion is one of 
the most common surgical procedures in gynecology and 
is amongst topics that are commonly investigated (2).
Definitive treatment for abortion is a surgical proce-
dure yet it is invasive and is not necessary for all females. 
Curettage may not be needed via expectation and medi-
cal treatment (1). According to the American college of 
obstetricians and gynecologists (2005), medical abor-
tion is an acceptable alternative for surgical procedures 
in pregnant women with gestational age of less than 49 
days based on the last menstrual period (LMP) (1).
Spontaneous abortion occurs in 10% - 20% of total preg-
nancies. Furthermore, 80% of abortions occur before the 
12th week of pregnancy. The mean gestational age of spon-
taneous abortion is nine weeks (2). Misoprostol is exten-
sively used for induction of labor in the second trimester 
of pregnancy, softening the cervix before using devices, 
curettage, hysteroscopy, therapeutic abortion, endome-
trial biopsy, early termination of pregnancy, treatment 
of incomplete abortion or missed abortion, treatment of 
postpartum hemorrhage and induction of labor at term 
(3). Misoprostol abortion rate is less than 90% in most 
studies and it has different side effects (4-7).
Application of 800 mcg of vaginal misoprostol results 
in abortion by stimulating the myometrium (1). Oral or 
vaginal misoprostol cause complete abortion in almost 
85% of cases within seven days before the 12th week (1). 
Mifepristone and a prostaglandin analogue for induc-
tion of abortion are preferred in nonsurgical methods. 
Using a combination of mifepristone and misoprostol is 
limited due to unavailability (8).
Letrozole is a non-steroidal aromatase inhibitor for the 
treatment of estrogen-dependent breast cancer. Estro-
gen is produced by aromatase enzyme activity from an-
drogens. Estrogens are necessary for continuation of the 
pregnancy. Letrozole reversibly and competitively bonds 
with the iron in cytochrome P450 and prevents the pro-
duction of estrogen by the enzyme aromatase. Aroma-
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tase inhibitors such as letrozole are widely used to treat 
patients with breast cancer (9-11).
These compounds directly inhibit estrogen biosynthe-
sis, lead to an increase in FSH secretion from the pituitary 
gland, yet don’t have the side effects of anti-estrogen on 
the endometrium and cervix. Non-steroidal aromatase 
third generation inhibitors such as letrozole have potent 
and reversible effects. The absence of anti-estrogenic ef-
fects of aromatase inhibitors, such as letrozole, is an-
other advantage. It prevents the interference of endome-
trium morphology and the cervix.
Aromatase inhibitors have no androgenic, progester-
one and estrogenic effects. It seems that aromatase inhib-
itors, such as letrozole, can open a new path and be a sig-
nificant therapeutic option in the treatment of females. 
Letrozole is an aromatase inhibitor that can amplify the 
effect of misoprostol in first trimester abortions.
Aromatase is an enzyme that is secreted from the placen-
ta, ovarian granulosa cells and other tissues, such as fat, 
muscle, brain and breast tissue. Letrozole has been used in 
the treatment of estrogen-dependent breast cancers (9-11).
In a clinical trial by Lee et al. (2011), complete abortion in 
the first trimester, in the misoprostol alone and the miso-
prostol with letrozole group was 72.6% and 86.9%, respec-
tively (P = 0.021) (12).
2. Objectives
The aim of this study was to compare the effect of miso-
prostol alone and misoprostol with letrozole for induc-
tion of abortion in the first trimester of pregnancy in the 
Qazvin city of Iran.
3. Patients and Methods
This randomized double-blind study was conducted 
during year 2013. All females that had referred to the 
Kowsar hospital of Qazvin and were candidates for thera-
peutic abortion with gestational age (GA) of less than 12 
weeks were considered as the target population. Seventy 
women with nonliving pregnancy were randomly allo-
cated to the control or intervention group (35 in the con-
trol group and 35 in the intervention group). Inclusion 
criteria were as follow:
1. Gestation age of less than 12 weeks, based on ultra-
sound results, on the first day of letrozole administration.
2. Mother’s age being more than 18 years.
3. Hemoglobin concentration (Hb) ≥ 10 gr/dL.
Exclusion criteria were as follow:
1. History of previous cesarean section.
2. History of adrenal disease, steroid-dependent can-
cer, liver disease, severe or recurrent, bronchial asth-
ma, evidence or history of thromboembolism, history 
of renal disease, blood pressure > 95 mmHg, history of 
smoking.
The patients received letrozole 10 mg as an oral dose (four 
tablets of 2.5 mg for three days) in the letrozole group. 
Four placebo tablets were given to the control group with 
the same instructions. Patients in both groups on the third 
day of the study were hospitalized and received a third 
dose of 800 μg of vaginal misoprostol in a single dose.
The patients were examined for opening of the inter-
nal os of the cervix every hour after the onset of uterine 
contractions (the time between administration of medi-
cation and opening of internal os was recorded). Two 
other duration times were recorded including the time 
between drug use and discharge initiation of pregnancy 
products and tissue, and time between drug use and com-
plete abortion (with completing the tissue rejection).
Vital signs were recorded every six hours. The patient 
side effects including fever, chills, nausea, vomiting, diar-
rhea, headache and abdominal pain were recorded in a 
form. Finally, vaginal sonography revealed the extent of 
the need for curettage.
Patient information was collected using a questionnaire. 
Data were analyzed using the student’s t-test, chi-square 
test and Fisher’s exact test. P values of < 0.05 were consid-
ered significant. Before the study, the researcher described 
the trend of the study and the patients who were willing to 
participate in the study signed a consent form.
4. Results
A total of 70 patients were enrolled. Two patients in the 
letrozole group had curettage before receiving misopro-
stol (second day) due to incomplete abortion. The mean 
age of patients in the letrozole and misoprostol, and 
misoprostol alone group was 26 ± 5.7 and 27.7 ± 5.6 years, 
respectively. Furthermore, 32.9% and 67.1% of patients had 
gestational age of less than seven weeks, and seven to 
twelve weeks, respectively.
Mean duration time of drug administration to open the 
os of the cervix was 6.0 ± 1.3 hours in all patients. Mean 
duration time to start prescribing tissue rejection was 
8.9 ± 2.0 hours in all patients. The mean duration time 
to complete abortion medication was 9.0 ± 2.0 hours in 
the patients. The complete abortion rate was 47.14% and 
curettage rate was 52.86% in all patients.
Mean duration time of drug administration to open the 
os of the cervix was 5.9 ± 1.5 hours in the letrozole and 
misoprostol group yet this was 6.1 ± 1.2 hours in the miso-
prostol alone group; this difference was not significant (P 
= 0.59) (Table 1).
Mean duration time between drug administration and 
opening of the os of the cervix was 5.2 ± 1.7 hours in pa-
tients with GA of less than seven weeks, and 6.1 ± 1.4 hours 
in patients with GA of between seven and twelve weeks 
from the misoprostol with letrozole group; this differ-
ence was not significant (P = 0.18) (Table 2).
From the total of 12 cases with complete abortion (GA 
of less than seven weeks), 41.7% were in the letrozole and 
misoprostol group and 85.3% were in the misoprostol 
alone group (P = 0.22). From the total of 21 cases with GA 
of between 7 and 12 weeks and complete abortion, 85.7% of 
the patients were in the letrozole plus misoprostol group 
and 14.3% were in the misoprostol group (P = 0.001).
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Table 1.  Time Span to Open the Cervix, Tissue Rejection, and Complete Abortion by Misoprostol With and Without Letrozole in the 
First Trimester of Pregnancy a
Observed Time Misoprostol Letrozole + Misoprostol P Value
Induction to opening of internal os time, h 6.1 ± 1.2 5.9 ± 1.5 0.59
Induction to abortion time, h 9.0 ± 1.7 8.9 ± 1.4 0.8
Induction to complete abortion time, h 9.0 ± 1.7 9.0 ± 2.4 1.0
a  Data are presented as mean ± SD.
Table 2.  Comparison of Misoprostol Alone or in Combination With Letrozole in Inducing Abortion During the First Trimester of 
Pregnancy by Pregnancy Age a
Observed Time Misoprostol P Value Letrozole + Misoprostol P Value
< 7, w 7 - 12, w < 7, w 7 - 12, w
Induction to internal os time, h 5.53 ± 1.24 6.6 ± 1.02 0.007 5.2 ± 1.7 6.1 ± 1.43 0.18
Induction to abortion time, h 8.13 ± 1.30 9.7 ± 1.70 0.006 7.8 ± 2.7 9.2 ± 2.2 0.19
Induction to complete abortion time, h 8.13 ± 1.3 1.7 ± 9.7 0.006 7.8 ± 2.7 9.3 ± 2.3 0.16
a  Data are presented as mean ± SD.
The success rate of excretion products in the first tri-
mester of pregnancy was higher in patients treated with 
misoprostol and letrozole, compared to misoprostol 
alone (69.7% vs. 30.3%, and P = 0.004). Complete abortion 
rate was 69.7% for the misoprostol and letrozole group, 
and 30.3% for the misoprostol alone group. This differ-
ence was statistically significant (P = 0.004). Drug side 
effects (e.g. nausea, dizziness, fatigue, abdominal pain, 
and chills) were not found in the study subjects.
5. Discussion
This study compared the effects of misoprostol com-
bined with letrozole, and misoprostol alone for the induc-
tion of abortion in the first trimester of pregnancy. Based 
on our observations, letrozole administration with miso-
prostol raised the rate of complete abortion in pregnan-
cies under 12 weeks in comparison with misoprostol alone.
The results of our study showed a 69.7% success rate of 
complete abortion with misoprostol and letrozole com-
pared to 30.3% with misoprostol alone (P = 0.004). In the 
study of Yeung et al. complete abortion, side effects, and 
the duration between induction and abortion (complete 
abortion induction interval) were studied. The results 
proved that the overall rate of complete abortion was 
95%, and one case (5%) had incomplete abortion and had 
to undergo curettage (13). The overall rate of complete 
abortion in patients with GA of less than 49 days was 100% 
(13). In contrast to our study, Yeung et al. used letrozole in 
combination with misoprostol regimen for seven days. 
The mean induction to abortion interval was not signifi-
cant in our study, similar to the findings of Yeung et al. 
Drug side effects such as nausea, dizziness, fatigue, ab-
dominal pain and chills were not found in our study. Lee 
et al. studied the use of letrozole in combination with le-
trozole, misoprostol and mifepristone (14), and complete 
abortion was higher in the letrozole plus misoprostol 
group, while in this group, the interval between induc-
tion and abortion was shorter than the other group. The 
success rate in the study of Lee et al. was 86.9% vs. 69.7% in 
our study with similar drug administration. In our study, 
the sample size was greater than the study of Lee et al. (70 
vs. 40), and they studied patients with gestational age of 
less than 63 days. In our study, there were a total of 12 cas-
es of complete abortion with GA of less than seven weeks 
(41.7%); five patients were in the letrozole and misopros-
tol group (85.3%), and seven cases were in the misoprostol 
alone group (P = 0.22).
There were a total of 21 cases of complete abortion with 
GA of between seven and twelve weeks (85.7 %); 18 patients 
in the letrozole and misoprostol group (14.3%) and three 
patients in the misoprostol group (P = 0.001). The success 
rate in use of letrozole and misoprostol, in patients with 
GA of seven to twelve weeks, was 85.7% at the disposal of 
pregnancy products, similar to the results of Lee et al. (14).
In another study that was conducted by Lee et al. (2011) 
(14), complete abortion was 86.9% with misoprostol and 
letrozole yet this was 72.6% in the misoprostol alone 
group, and the difference was statistically significant (P 
= 0.021). Common side effects (abdominal pain, nausea 
and vomiting) were found in 3.8% of cases in the letrozole 
and misoprostol group, and 19% in the misoprostol alone 
group; the difference being statistically significant (P = 
0.043) (12). In contrast to this study, our success rate was 
lower, yet no side effects were recorded, and the differ-
ence in our study was not statistically significant.
In the study of Chai et al. complete abortion rate was 
98% with the addition of letrozole to mifepristone and 
misoprostol, and the interval from induction to abortion 
was 5.1 hours. In our study no adverse effects were report-
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ed yet in the study of Chai et al. (15), 2% of cases needed 
suction due to massive bleeding.
Differences in studied populations, genetic diversity 
and distribution of receptors, the application of medi-
cations, PH of the vagina, drug manufacturers, GA and 
sample size were confounding factors that must be con-
sidered.
Letrozole is an aromatase inhibitor that has an effect on 
the production of estrogen in the mitochondria, ovaries 
and the placenta (16, 17). Previous studies have shown 
that letrozole is effective in reducing estrogen and does 
not affect progesterone (13, 17). Furthermore, recent stud-
ies have shown that letrozole has no effect on uterine 
contractions (18). The mechanism of action of letrozole 
is different from that of more expensive drugs such as 
mifepristone.
The mechanism of action of letrozole could explain the 
number of days prescribed for maximum efficacy. Anoth-
er factor that was noted was that letrozole reduces bleed-
ing after abortion, which makes it a good therapeutic op-
tion, since bleeding is one of the major concerns (19, 20). 
Loss of pregnancy during the first trimester is one of the 
most common pregnancy complications. Its incidence 
is 50% (21). Surgical termination of pregnancy is very ef-
fective yet has many complications such as infection, 
uterine perforation, Asherman’s syndrome and future 
infertility of women (22). Expectant management may 
also be useful in some individuals yet it is unpredictable 
(23). Medical termination of pregnancy is a safer method. 
Medical termination of pregnancy by mifepristone was 
recommended, yet mifepristone is an expensive drug 
and is not available everywhere (8). On the basis of this 
study, we recommend the use of letrozole plus misopro-
stol for the treatment of abortion due to lower costs and 
greater chances of complete abortion (without special ef-
fects). As far as we know, in our country, this was the first 
study on the combination of letrozole with misoprostol 
in comparison with misoprostol alone to terminate preg-
nancies under 12 weeks.
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